Martin F Fromm

Summary

Affiliation: University of Erlangen-Nuremberg
Country: Germany

Publications

  1. doi request reprint Transporter-mediated drug-drug interactions
    Fabian Müller
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Fahrstrasse 17, 91054 Erlangen, Germany
    Pharmacogenomics 12:1017-37. 2011
  2. ncbi request reprint Importance of P-glycoprotein at blood-tissue barriers
    Martin F Fromm
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen Nuremberg, Fahrstrasse 17, 91054 Erlangen, Germany
    Trends Pharmacol Sci 25:423-9. 2004
  3. doi request reprint Inhibition of hepatic uptake transporters by flavonoids
    Kathrin Mandery
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Fahrstraße 17, 91054 Erlangen, Germany
    Eur J Pharm Sci 46:79-85. 2012
  4. doi request reprint Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine
    Fabian Müller
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Fahrstrasse 17, 91054 Erlangen, Germany
    Biochem Pharmacol 86:808-15. 2013
  5. doi request reprint The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members
    Sabine Klatt
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Erlangen, Germany
    Basic Clin Pharmacol Toxicol 112:244-50. 2013
  6. ncbi request reprint Transport of asymmetric dimethylarginine (ADMA) by cationic amino acid transporter 2 (CAT2), organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1)
    Joachim Strobel
    Emil Fischer Center, Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Fahrstraße 17, 91054, Erlangen, Germany
    Amino Acids 45:989-1002. 2013
  7. doi request reprint The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost
    Michaela E Kraft
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University of Erlangen Nuremberg, Erlangen, Germany
    Invest Ophthalmol Vis Sci 51:2504-11. 2010
  8. doi request reprint Organic cation transporter 3: expression in failing and nonfailing human heart and functional characterization
    Thomas F Solbach
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Fahrstrasse 17, Erlangen, Germany
    J Cardiovasc Pharmacol 58:409-17. 2011
  9. ncbi request reprint In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions
    Jürgen Kindla
    Friedrich Alexander University Erlangen Nuremberg, Institute of Experimental and Clinical Pharmacology and Toxicology, Department of Clinical Pharmacology and Clinical Toxicology, Fahrstrasse 17, D 91054 Erlangen, Germany
    Expert Opin Drug Metab Toxicol 5:489-500. 2009
  10. doi request reprint Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake
    Jorg Konig
    Institute of Experimental and Clinical Pharmacology and Toxicology, Universitat Erlangen Nurnberg, Erlangen, Germany
    Drug Metab Dispos 39:1097-102. 2011

Detail Information

Publications83

  1. doi request reprint Transporter-mediated drug-drug interactions
    Fabian Müller
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Fahrstrasse 17, 91054 Erlangen, Germany
    Pharmacogenomics 12:1017-37. 2011
    ..Genotype-dependent drug-drug interactions are also discussed...
  2. ncbi request reprint Importance of P-glycoprotein at blood-tissue barriers
    Martin F Fromm
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen Nuremberg, Fahrstrasse 17, 91054 Erlangen, Germany
    Trends Pharmacol Sci 25:423-9. 2004
    ....
  3. doi request reprint Inhibition of hepatic uptake transporters by flavonoids
    Kathrin Mandery
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Fahrstraße 17, 91054 Erlangen, Germany
    Eur J Pharm Sci 46:79-85. 2012
    ..Taken together, these in vitro studies showed that the investigated flavonoids inhibit the OATP1B1- and OATP1B3-mediated drug transport, which could be a mechanism for food-drug interactions in humans...
  4. doi request reprint Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine
    Fabian Müller
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Fahrstrasse 17, 91054 Erlangen, Germany
    Biochem Pharmacol 86:808-15. 2013
    ..9 μM. Lamivudine is a substrate of renal drug transporters OCT2, MATE1, and MATE2-K. Concomitant administration of drugs that inhibit these transporters could decrease renal clearance of lamivudine...
  5. doi request reprint The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members
    Sabine Klatt
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Erlangen, Germany
    Basic Clin Pharmacol Toxicol 112:244-50. 2013
    ..In conclusion, these in vitro results demonstrate that several oral antidiabetic drugs may influence hepatic OATP-mediated drug uptake. The in vivo consequences of these results have to be analysed in further studies...
  6. ncbi request reprint Transport of asymmetric dimethylarginine (ADMA) by cationic amino acid transporter 2 (CAT2), organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1)
    Joachim Strobel
    Emil Fischer Center, Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Fahrstraße 17, 91054, Erlangen, Germany
    Amino Acids 45:989-1002. 2013
    ..Transport kinetics of CAT2A, CAT2B, and OCT2 indicate a low affinity, high capacity transport, which may be relevant for renal and hepatic elimination of ADMA or L-arginine. ..
  7. doi request reprint The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost
    Michaela E Kraft
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University of Erlangen Nuremberg, Erlangen, Germany
    Invest Ophthalmol Vis Sci 51:2504-11. 2010
    ....
  8. doi request reprint Organic cation transporter 3: expression in failing and nonfailing human heart and functional characterization
    Thomas F Solbach
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Fahrstrasse 17, Erlangen, Germany
    J Cardiovasc Pharmacol 58:409-17. 2011
    ..6-15.8 μM). Altogether, OCT3 might be important for the cardiac disposition of cationic drugs, and OCT3-dependent interaction with concomitantly administered compounds may limit their disposition and effect...
  9. ncbi request reprint In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions
    Jürgen Kindla
    Friedrich Alexander University Erlangen Nuremberg, Institute of Experimental and Clinical Pharmacology and Toxicology, Department of Clinical Pharmacology and Clinical Toxicology, Fahrstrasse 17, D 91054 Erlangen, Germany
    Expert Opin Drug Metab Toxicol 5:489-500. 2009
    ..Alteration of transporter-mediated drug uptake by concomitantly administered drugs may also result in a change in drug pharmacokinetics. These uptake transporter-mediated drug-drug interactions are the focus of this review...
  10. doi request reprint Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake
    Jorg Konig
    Institute of Experimental and Clinical Pharmacology and Toxicology, Universitat Erlangen Nurnberg, Erlangen, Germany
    Drug Metab Dispos 39:1097-102. 2011
    ..These in vitro data indicate that OATP-mediated uptake and its modification by genetic factors and comedications may play a role for mesalazine effects...
  11. doi request reprint Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser
    Oliver Zolk
    Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen Nuremberg, Erlangen, Germany
    Drug Metab Dispos 37:1312-8. 2009
    ..808G>T single nucleotide polymorphism significantly alters uptake of endogenous compounds and drugs. Moreover, for selected compounds the extent of OCT2-mediated drug interactions could depend on OCT2 c.808G>T genotype...
  12. doi request reprint Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport
    Juergen Kindla
    Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen Nuremberg, Erlangen, Germany
    Drug Metab Dispos 39:1047-53. 2011
    ....
  13. doi request reprint Transporters and drug-drug interactions: important determinants of drug disposition and effects
    Jorg Konig
    Institute of Experimental and Clinical Pharmacology and Toxicology, Clinical Pharmacology and Clinical Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Germany
    Pharmacol Rev 65:944-66. 2013
    ..Further work is required regarding a better understanding of the role of the drug metabolism-drug transport interplay for drug-drug interactions and on the extrapolation of in vitro findings to the in vivo (human) situation...
  14. doi request reprint Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1)
    Joachim Strobel
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Fahrstraße 17, 91054 Erlangen, Germany
    J Mol Cell Cardiol 53:392-400. 2012
    ..In its physiological concentration range ADMA is unlikely to impair CAT1-mediated transport of l-arginine. Conversely, high (but still physiological) concentrations of l-arginine can inhibit CAT1-mediated cellular uptake of ADMA...
  15. doi request reprint Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1
    Kathrin Mandery
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen Nuremberg, Fahrstraße 17, 91054 Erlangen, Germany
    Biochem Pharmacol 80:1746-53. 2010
    ..5μM, OATP2B1: 14.1μM). These data indicate that modification of OATP1A2 and OATP2B1 transport activity by apigenin, kaempferol, and quercetin may be a mechanism for food-drug or drug-drug interactions in humans...
  16. pmc Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine
    Fabian Müller
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Fahrstrasse 17, 91054 Erlangen, Germany
    Antimicrob Agents Chemother 55:3091-8. 2011
    ..Concomitantly administered MATE1 inhibitors are likely to modify the renal secretion of chloroquine...
  17. ncbi request reprint Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2)
    Oliver Zolk
    Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen Nuremberg, Fahrstr 17, 91054, Erlangen, Germany
    Naunyn Schmiedebergs Arch Pharmacol 379:337-48. 2009
    ..0 A. Taken together, our data identify structural determinants for inhibitor interactions with OCT2...
  18. pmc Alanine-glyoxylate aminotransferase 2 (AGXT2) polymorphisms have considerable impact on methylarginine and β-aminoisobutyrate metabolism in healthy volunteers
    Anja Kittel
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Erlangen, Germany
    PLoS ONE 9:e88544. 2014
    ..In conclusion, SNPs of AGXT2 affect plasma as well as urinary BAIB and SDMA concentrations linking methylarginine metabolism to the common genetic trait of hyper-β-aminoisobutyric aciduria...
  19. doi request reprint Functional and structural relevance of conserved positively charged lysine residues in organic anion transporting polypeptide 1B3
    Kathrin Mandery
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Erlangen, Germany
    Mol Pharmacol 80:400-6. 2011
    ..001), respectively, indicating that the positive charge of lysine at position 399 is necessary for an unimpaired cell surface expression. Furthermore, we provide a summary of amino acids, which influence the transport activity of OATP1B3...
  20. doi request reprint Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects
    Christina Fahrmayr
    Department of Clinical Pharmacology and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen Nuremberg, Germany
    Drug Metab Rev 42:380-401. 2010
    ....
  21. ncbi request reprint Expression and localization of the uptake transporters OATP2B1, OATP3A1 and OATP5A1 in non-malignant and malignant breast tissue
    Juergen Kindla
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen Nuremberg, Erlangen, Germany
    Cancer Biol Ther 11:584-91. 2011
    ....
  22. ncbi request reprint Animal models and intestinal drug transport
    Hartmut Glaeser
    Friedrich Alexander University Erlangen Nuremberg, Institute of Experimental and Clinical Pharmacology and Toxicology, Erlangen, Germany
    Expert Opin Drug Metab Toxicol 4:347-61. 2008
    ..During the last decade, various animal models lacking drug transporters have been generated in order to investigate the role of transporters for drug absorption, distribution and elimination...
  23. ncbi request reprint The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3
    Annick Seithel
    Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen Nuremberg, 91054 Erlangen, Germany
    Drug Metab Dispos 35:779-86. 2007
    ..In summary, these results indicate that alterations of uptake transporter function by certain macrolides/ketolides have to be considered as a potential additional mechanism underlying drug-drug interactions...
  24. ncbi request reprint Clinical relevance of drug efflux pumps in the gut
    Shingen Misaka
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Erlangen, Germany
    Curr Opin Pharmacol 13:847-52. 2013
    ..The role of polymorphisms in genes encoding for these transporters will also be discussed. Taken together this review will focus on the role of intestinal export pumps using selected examples from clinical studies in humans. ..
  25. doi request reprint Transporter gene expression in human head and neck squamous cell carcinoma and associated epigenetic regulatory mechanisms
    Oliver Zolk
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Erlangen, Germany
    Am J Pathol 182:234-43. 2013
    ....
  26. doi request reprint Characterization of ursodeoxycholic and norursodeoxycholic acid as substrates of the hepatic uptake transporters OATP1B1, OATP1B3, OATP2B1 and NTCP
    Jorg Konig
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Germany
    Basic Clin Pharmacol Toxicol 111:81-6. 2012
    ..34-fold. NorUDCA was not significantly transported by NTCP. The low uptake rates suggest that OATP1B1, OATP1B3, OATP2B1 and NTCP are not relevant for hepatocellular uptake and effects of UDCA and norUDCA in human beings...
  27. ncbi request reprint The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members
    Annick Seithel
    Friedrich Alexander University Erlangen Nuremberg, Institute of Experimental and Clinical Pharmacology and Toxicology, Fahrstrasse 17, 91054 Erlangen, Germany
    Expert Opin Drug Metab Toxicol 4:51-64. 2008
    ..This review focuses on consequences of these genetic variations and summarises in vivo as well as in vitro analyses demonstrating the impact of polymorphisms in genes encoding OATPs on transport and pharmacokinetics of drugs...
  28. doi request reprint Gender is an important determinant of the disposition of the loop diuretic torasemide
    Ulrike Werner
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Martinistr 52, 20146 Hamburg, Germany
    J Clin Pharmacol 50:160-8. 2010
    ....
  29. ncbi request reprint Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic
    Burkhard Hinz
    Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen Nurnberg, Fahrstrasse 17, D 91054 Erlangen, Germany
    FASEB J 21:2343-51. 2007
    ..In view of the observed COX-1 suppression, physicochemical factors (lack of acidity) rather than differential COX-1 inhibition may be responsible for dipyrone's favorable gastrointestinal tolerability compared with acidic COX inhibitors...
  30. ncbi request reprint Non-synonymous polymorphisms in the human SLCO1B1 gene: an in vitro analysis of SNP c.1929A>C
    Annick Seithel
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen Nuremberg, Fahrstrasse 17, Erlangen, Germany
    Mol Genet Genomics 279:149-57. 2008
    ..1929A>C had no effect on the hepatic OATP1B1 protein expression and on the transport properties. Therefore, it is unlikely that c.1929A>C contributes to interindividual variability in drug disposition...
  31. ncbi request reprint Pharmacogenomics of human OATP transporters
    Jorg Konig
    Institute for Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen Nuremberg, Fahrstr 17, 91054, Erlangen, Germany
    Naunyn Schmiedebergs Arch Pharmacol 372:432-43. 2006
    ..In this review, we summarise the current knowledge on genetic variations in transporter genes encoding human OATP family members and their functional consequences analysed by in vitro and in vivo studies...
  32. ncbi request reprint Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation
    Martin F Fromm
    Institute of Experimental and Clinical Pharmacology and Toxicology, Clinical Pharmacology and Clinical Toxicology, Friedrich Alexander University Erlangen Nuremberg, Germany
    Eur J Clin Pharmacol 63:1129-33. 2007
    ..This study was undertaken to estimate whether the CYP3A5 genotype can explain a relevant portion of pharmacokinetic interindividual variability...
  33. ncbi request reprint Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans
    Ulrike Werner
    Department of Experimental and Clinical pharmacology and Toxicology and II Medical Clinic, Friedrich Alexander University Erlangen Nuremberg, Erlangen, Germany
    Clin Pharmacol Ther 74:130-7. 2003
    ..Therefore the objective of this study was to examine the effect of celecoxib and rofecoxib on the pharmacokinetics of the clinically relevant CYP2D6 substrate metoprolol...
  34. doi request reprint Activation of negative regulators of the hypoxia-inducible factor (HIF) pathway in human end-stage heart failure
    Oliver Zolk
    Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen Nuremberg, Fahrstr 17, 91054 Erlangen, Germany
    Biochem Biophys Res Commun 376:315-20. 2008
    ..Although negative regulators of HIF were induced, the HIF pathway obviously remains activated in chronic human heart failure, because prototype HIF target genes, such as ABCG2, VEGF, and BNIP3, were significantly induced...
  35. doi request reprint Drug transport by breast cancer resistance protein
    Maren Poguntke
    University of Erlangen Nuremberg, Institute of Experimental and Clinical Pharmacology and Toxicology, Fahrstr 17, 91054 Erlangen, Germany
    Expert Opin Drug Metab Toxicol 6:1363-84. 2010
    ..Beyond multi-drug resistance, experimental and recent clinical studies demonstrate a role for ABCG2 as a determinant of drug pharmacokinetic, safety and efficacy profiles...
  36. doi request reprint Potentially inappropriate medications in a large cohort of patients in geriatric units: association with clinical and functional characteristics
    Martin F Fromm
    Institute of Experimental and Clinical Pharmacology and Toxicology, Emil Fischer Center, Friedrich Alexander Universitat Erlangen Nurnberg, Fahrstraße 17, 91054 Erlangen, Germany
    Eur J Clin Pharmacol 69:975-84. 2013
    ..However, it is unclear whether use of PIM at discharge from specialized geriatric units is associated with altered clinical characteristics...
  37. doi request reprint Effect of the rs168924 single-nucleotide polymorphism in the SLC6A2 catecholamine transporter gene on blood pressure in Caucasians
    Oliver Zolk
    Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen Nuremberg, Erlangen, Germany
    J Clin Hypertens (Greenwich) 14:293-8. 2012
    ..Unlike previous findings in a Japanese population, in our Caucasian study cohort the presence of the minor rs168924 G allele was associated with lower prevalence of hypertension...
  38. ncbi request reprint Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein
    Iouri Bachmakov
    Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen Nuremberg, Fahrstrasse 17, 91054 Erlangen, Germany
    Fundam Clin Pharmacol 20:273-82. 2006
    ..In addition, the beta-adrenoceptor antagonists propranolol and carvedilol significantly inhibit P-glycoprotein function thereby possibly contributing to drug interactions in humans (e.g. digoxin-carvedilol and cyclosporine-carvedilol)...
  39. ncbi request reprint Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies
    Sonja Eberl
    Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen Nuremberg, Erlangen, Germany
    Clin Pharmacokinet 46:1039-49. 2007
    ....
  40. doi request reprint Different indications, warnings and precautions, and contraindications for the same drug--an international comparison of prescribing information for commonly used psychiatric drugs
    Barbara Pfistermeister
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Erlangen, Germany
    Pharmacoepidemiol Drug Saf 22:329-33. 2013
    ..We aim to derive an internationally applicable data set to improve prescription safety of psychiatric drugs...
  41. pmc Drug transporter regulation in tumors by DNA methylation
    Oliver Zolk
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander Universitat Erlangen Nurnberg, Fahrstrasse 17, 91054 Erlangen, Germany
    Genome Med 4:10. 2012
    ..See research article http://www.genomemedicine.com/content/3/12/82...
  42. doi request reprint Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1
    Iouri Bachmakov
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen Nuremberg, Erlangen, Germany
    Diabetes 57:1463-9. 2008
    ....
  43. doi request reprint Influence of cyclooxygenase inhibitors on the function of the prostaglandin transporter organic anion-transporting polypeptide 2A1 expressed in human gastroduodenal mucosa
    Kathrin Mandery
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen Nuremberg, Erlangen, Germany
    J Pharmacol Exp Ther 332:345-51. 2010
    ....
  44. doi request reprint ATP-binding cassette transporters in human heart failure
    Thomas F Solbach
    Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen Nuremberg, Fahrstr 17, 91054 Erlangen, Germany
    Naunyn Schmiedebergs Arch Pharmacol 377:231-43. 2008
    ..These results suggest that altered ABC transporter expression in failing hearts might contribute to impaired channel conductance or might affect the cardiac disposition of drugs...
  45. ncbi request reprint Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein
    Iouri Bachmakov
    Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen Nuremberg, Fahrstrasse 17, 91054 Erlangen, Germany
    Naunyn Schmiedebergs Arch Pharmacol 371:195-201. 2005
    ..In addition, propafenone and its two major metabolites 5-hydroxypropafenone and N-desalkylpropafenone are inhibitors of human P-glycoprotein and therefore contribute to the digoxin-propafenone interaction observed in humans...
  46. ncbi request reprint Functional analysis of the polymorphism -211C>T in the regulatory region of the human ABCC3 gene
    Ulrike Gradhand
    Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen Nuremberg, Fahrstr 17, 91054 Erlangen, Germany
    Life Sci 80:1490-4. 2007
    ..Whether other tissue specific mechanisms reveal an impact of this SNP on the in vivo regulation of MRP3 remains to be determined...
  47. ncbi request reprint Lipid-lowering response to statins is affected by CYP3A5 polymorphism
    Kari T Kivistö
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenetics 14:523-5. 2004
    ..These findings suggest that CYP3A5 may be a genetic determinant of interindividual differences in response to certain statins...
  48. ncbi request reprint Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers
    Dierk Werner
    Department of Cardiology, Helios Hospital Schwerin, Schwerin, Germany
    Clin Pharmacokinet 47:323-32. 2008
    ....
  49. ncbi request reprint The association of ABCB1 polymorphisms and elevated serum digitoxin concentrations in geriatric patients
    Charalampos Dragonas
    Institute for Biomedicine of Aging, Department of Internal Medicine V Geriatrics, University of Erlangen Nuremberg, Nuremberg, Germany
    Eur J Clin Pharmacol 64:367-72. 2008
    ..Our objective was to examine the association of ABCB1 C3435T genotype and elevated serum digitoxin concentrations (SDC) in a cohort of 77 geriatric patients consecutively admitted to a geriatric department over a 12-month period...
  50. ncbi request reprint Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice
    Kari T Kivistö
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Naunyn Schmiedebergs Arch Pharmacol 370:124-30. 2004
    ..As several statins are P-glycoprotein substrates, beneficial as well as adverse effects of the statins might be affected by interindividual differences in P-glycoprotein expression or function caused by, e.g., the MDR1 polymorphism...
  51. ncbi request reprint Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters
    Hartmut Glaeser
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacol Ther 71:131-40. 2002
    ..Because enterocytes are constantly shed in large numbers into the gut lumen, this study investigated whether these cells could be collected with a multilumen perfusion catheter and whether they are functionally active...
  52. ncbi request reprint High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
    Mikko Niemi
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenetics 14:429-40. 2004
    ..No significant associations were found between OATP-B, MRP2 or MDR1 polymorphisms and the pharmacokinetics of pravastatin. These results suggest that haplotypes are more informative in predicting the OATP-C phenotype than single SNPs...
  53. ncbi request reprint Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1)
    Monika Hitzl
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenetics 14:309-18. 2004
    ..Taken together, the MDR1 polymorphisms C3435T and G2677T are associated with altered P-glycoprotein expression in the human placenta, and may have clinical consequences due to genetically determined, variable drug exposure of the fetus...
  54. ncbi request reprint Differential expression and function of CYP2C isoforms in human intestine and liver
    Florian Läpple
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology and Robert Bosch Hospital, Stuttgart, University Hospital Mannheim, Mannheim, Germany
    Pharmacogenetics 13:565-75. 2003
    ....
  55. ncbi request reprint P-glycoprotein-mediated intestinal and biliary digoxin transport in humans
    Siegfried Drescher
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Clin Pharmacol Ther 73:223-31. 2003
    ..Intestinal transport by P-glycoprotein is a recently recognized determinant of drug disposition. However, direct measurements of transporter-mediated drug elimination into isolated segments of human small intestine are lacking...
  56. ncbi request reprint The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans
    Martin F Fromm
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstr 112, 70376 Stuttgart, Germany
    Adv Drug Deliv Rev 54:1295-310. 2002
    ..This review discusses the currently available data on the influence of MDR1 polymorphisms on P-glycoprotein tissue expression, drug disposition, treatment outcome and disease risk...
  57. ncbi request reprint Genetic polymorphisms of the human MDR1 drug transporter
    Matthias Schwab
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Annu Rev Pharmacol Toxicol 43:285-307. 2003
    ..Potential implications of MDR1 polymorphisms for drug disposition, drug effects, and disease risk are discussed...
  58. ncbi request reprint Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4
    Rajinder K Bhardwaj
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    J Pharmacol Exp Ther 302:645-50. 2002
    ....
  59. pmc MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine
    Siegfried Drescher
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Br J Clin Pharmacol 53:526-34. 2002
    ..Using fexofenadine, a known P-glycoprotein substrate, the hypothesis was tested whether this polymorphism also affects the disposition of other drugs in humans...
  60. ncbi request reprint Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine
    Oliver Burk
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    J Biol Chem 277:24280-8. 2002
    ..We conclude that the presence of the ER6 motif of CYP3A4 mediates the high expression of CYP3A7 in subjects carrying CYP3A7*1C...
  61. ncbi request reprint Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans
    Hartmut Glaeser
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Clin Pharmacol Ther 76:230-8. 2004
    ....
  62. ncbi request reprint Effect of amiodarone on the plasma levels of metoprolol
    Dierk Werner
    Department of Cardiology, Helios Clinic, Schwerin, Germany
    Am J Cardiol 94:1319-21. 2004
    ..On average, metoprolol plasma concentration is doubled after an amiodarone loading dose (1.2 g/day over a period of 6 days). However, the individual amount of this drug interaction depends on the CYP2D6 genotype...
  63. ncbi request reprint Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin
    Mikko Niemi
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenet Genomics 16:565-8. 2006
    ..However, the present study had sufficient power to detect only a considerably smaller rifampicin-induced increase in 4beta-hydroxycholesterol in carriers of the SLCO1B1 c.521C allele compared to subjects with the reference genotype...
  64. ncbi request reprint Functional interaction of intestinal CYP3A4 and P-glycoprotein
    Kari T Kivistö
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Fundam Clin Pharmacol 18:621-6. 2004
    ..Further understanding this interplay would be potentially useful during drug development to solve bioavailability problems of new drug entities...
  65. ncbi request reprint Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor
    Oliver Burk
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Mol Pharmacol 67:1954-65. 2005
    ..In conclusion, activation of PXR and CAR and especially the resulting induction of CYP3A4 and MDR1 demonstrate that artemisinin has a higher risk of potential drug interactions than anticipated previously...
  66. pmc Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1)
    Mikko Niemi
    Br J Clin Pharmacol 59:602-4. 2005
  67. ncbi request reprint Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1
    Stefan Oswald
    Department of Clinical Pharmacology, University of Greifswald, Greifswald, Germany
    Pharmacogenet Genomics 18:559-68. 2008
    ....
  68. ncbi request reprint Grapefruit juice ingestion significantly reduces talinolol bioavailability
    Ute I Schwarz
    Institute of Clinical Pharmacology, Medical Faculty, Technical University, and Medical Department I, Technical University Hospital, Dresden
    Clin Pharmacol Ther 77:291-301. 2005
    ....
  69. ncbi request reprint Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux
    Svitlana Igel
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacokinet 46:777-85. 2007
    ..We therefore investigated whether inhibition of intestinal P-glycoprotein-mediated efflux by quinidine leads to increased absorption of the P-glycoprotein substrate digoxin...
  70. ncbi request reprint Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans
    Laurent Becquemont
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology and Department of Internal Medicine I, Robert Bosch Hospital, Stuttgart, Germany
    Clin Pharmacol Ther 79:449-60. 2006
    ..The main objective of this study was to determine whether UDCA alters the pharmacokinetics of digoxin and midazolam. The secondary objective was to determine whether the intestinal expression of P-gp and CYP3A4 is increased by UDCA...
  71. ncbi request reprint MDR1 genotype-dependent regulation of the aldosterone system in humans
    Oliver Zolk
    Institute of Clinical and Experimental Pharmacology and Toxicology, University of Erlangen Nuremberg, Erlangen, Germany
    Pharmacogenet Genomics 17:137-44. 2007
    ....
  72. ncbi request reprint Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration
    Dagmar Busse
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Naunyn Schmiedebergs Arch Pharmacol 366:218-25. 2002
    ..The magnitude of the decrease, however, is unlikely to be of clinical significance...
  73. ncbi request reprint CYP3A5 genotype is associated with elevated blood pressure
    Martin F Fromm
    Institute of Clinical and Experimental Pharmacology and Toxicology, University of Erlangen Nuremberg, Erlangen, Germany
    Pharmacogenet Genomics 15:737-41. 2005
    ..We interpret the lower serum aldosterone concentration in the genotype group with the elevated systolic blood pressure as a counter-regulatory mechanism to attenuate the increased blood pressure associated with the CYP3A5*3/*3 genotype...
  74. doi request reprint Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
    Dietmar Trenk
    Herz Zentrum Bad Krozingen, Bad Krozingen, Germany
    J Am Coll Cardiol 51:1925-34. 2008
    ....
  75. ncbi request reprint Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene
    Andreas Johne
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, Germany
    Clin Pharmacol Ther 72:584-94. 2002
    ..According to earlier data, homozygous TT of the exon 26 complementary deoxyribonucleic acid (cDNA) 3435C>T polymorphism was associated with low P-gp expression in the human intestine...
  76. ncbi request reprint Genetically determined differences in P-glycoprotein function: implications for disease risk
    Martin F Fromm
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstr 112, 70376 Stuttgart, Germany
    Toxicology 181:299-303. 2002
    ....
  77. ncbi request reprint Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis
    Matthias Schwab
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Gastroenterology 124:26-33. 2003
    ..Because the MDR1 single nucleotide polymorphism C3435T is associated with lower intestinal P-glycoprotein expression, we tested whether this polymorphism predisposes to development of ulcerative colitis...
  78. ncbi request reprint Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein
    Karin Dilger
    Dr Falk Pharma GmbH, Freiburg, Germany
    Inflamm Bowel Dis 10:578-83. 2004
    ..Therefore, drug secretion via P-glyco-protein into gut lumen might play a more important role in pharmacokinetics and pharmacodynamics of these corticosteroids than currently appreciated in gastroenterological practice...
  79. ncbi request reprint Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens
    Oliver von Richter
    Dr Margarete Fisher Bosch Institute of Clinical Pharmacology, and Department of Surgery, Robert Bosch Hospital, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Clin Pharmacol Ther 75:172-83. 2004
    ..Our objectives were to determine the content of cytochrome P450 (CYP) 3A4, CYP3A5, and P-glycoprotein and to measure CYP3A4-dependent catalytic activity in paired human small intestinal and liver specimens...
  80. ncbi request reprint CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study
    Kari T Kivistö
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Am J Pharmacogenomics 5:191-5. 2005
    ..The aim of this study was to address the presently controversial question of whether cytochrome P450 (CYP) 3A5 polymorphism is associated with hypertension...
  81. ncbi request reprint Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver
    Thomas Lang
    Epidauros Biotechnology, Pharmacogenetics Laboratory, Am Neuland 1, 82347 Bernried, Germany
    Pharmacogenetics 14:155-64. 2004
    ..To determine the genetic variability of multidrug resistance protein 3 (MRP3)...
  82. ncbi request reprint Clinical aspects of the MDR1 (ABCB1) gene polymorphism
    Michel Eichelbaum
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Ther Drug Monit 26:180-5. 2004
    ..Clinical studies on the effects of the C3435T polymorphism and drug treatment with cardiac glycosides, the immunosuppressants cyclosporine and tacrolimus, HIV protease inhibitors, and tricyclic antidepressants are discussed...
  83. ncbi request reprint Influence of omeprazole on multidrug resistance protein 3 expression in human liver
    Monika Hitzl
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    J Pharmacol Exp Ther 304:524-30. 2003
    ..05), in HepG2 cells treated with omeprazole. Finally, MRP3 was induced in HepG2 cells by beta-naphthoflavone. In summary, treatment with omeprazole and beta-naphthoflavone is a determinant of variable human hepatic MRP3 expression...